Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

v2.4.0.8
Condensed Consolidated Financial Statement Detail (Tables)
6 Months Ended
Jun. 30, 2013
Condensed Consolidated Financial Statement Detail [Abstract]  
Outstanding securities considered anti-dilutive
Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

 
 
Three Months Ended June 30,
   
Six Months Ended June 30,
 
 
 
2013
   
2012
   
2013
   
2012
 
Common stock options and restricted stock units
   
7,346
     
5,121
     
7,084
     
5,566
 
Warrants for common stock
   
16,176
     
16,702
     
16,176
     
11,079
 
Total
   
23,522
     
21,823
     
23,260
     
16,645
 
Accrued liabilities
Accrued liabilities consisted of the following at June 30, 2013 and December 31, 2012 (in thousands):

 
 
June 30,
2013
   
December 31,
2012
 
Accrued payroll and other benefits
 
$
2,604
   
$
2,461
 
Accrued management incentive compensation
   
2,177
     
3,978
 
Accrued clinical trial costs
   
659
     
4,702
 
Other
   
1,189
     
1,904
 
Total
 
$
6,629
   
$
13,045